VARIABILITY IN THE PHARMACOKINETICS OF EPIRUBUCIN - A POPULATION ANALYSIS

被引:46
作者
WADE, JR
KELMAN, AW
KERR, DJ
ROBERT, J
WHITING, B
机构
[1] UNIV GLASGOW,GARDINER INST,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND
[2] W SCOTLAND HLTH BOARDS,DEPT CLIN PHYS & BIOENGN,GLASGOW G4 9LF,SCOTLAND
[3] UNIV GLASGOW,CANC RES CTR,DEPT MED ONCOL,GLASGOW G61 1BD,SCOTLAND
[4] FDN BERGONIE,F-33076 BORDEAUX,FRANCE
关键词
D O I
10.1007/BF00686009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Population pharmacokinetic analysis of the anticancer agent epirubicin was carried out using the program NONMEM. Data were available from 36 patients aged 20-73 years, of whom 23 were women. All subjects exhibited normal liver and renal function. Epirubicin was given as a short-term i. v. infusion over the dose range of 25-100 mg/m2, and an average of 11 plasma samples/subject were taken for a period of up to 72 h after each dose. A Two compartment model was fitted to the data, characterised by the parameters clearance, volume of the central compartment, alpha and beta. Clearance was tested as a linear function of various demographic and/or biochemical features. A significant proportion of the variability in clearance could be attributed to sex, and also to age in women. For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h. Such differences in clearance might be important in the selection of epirubicin dose regimens.
引用
收藏
页码:391 / 395
页数:5
相关论文
共 18 条
[1]  
BEAL S, 1979, NONMEM USERS GUIDE 1
[2]  
CAMAGGI CM, 1982, CANCER TREAT REP, V66, P1819
[3]   EPIRUBICIN - A REVIEW OF THE PHARMACOLOGY, CLINICAL ACTIVITY, AND ADVERSE-EFFECTS OF AN ADRIAMYCIN ANALOG [J].
CERSOSIMO, RJ ;
HONG, WK .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :425-439
[4]   PHARMACOKINETICS OF ANTHRACYCLINES [J].
EKSBORG, S .
ACTA ONCOLOGICA, 1989, 28 (06) :873-876
[5]   CLINICAL PHARMACOKINETICS-PHARMACODYNAMICS OF ANTICANCER DRUGS [J].
EVANS, WE ;
RELLING, MV .
CLINICAL PHARMACOKINETICS, 1989, 16 (06) :327-336
[6]   CLINICAL PHARMACODYNAMICS OF HIGH-DOSE METHOTREXATE IN ACUTE LYMPHOCYTIC-LEUKEMIA - IDENTIFICATION OF A RELATION BETWEEN CONCENTRATION AND EFFECT [J].
EVANS, WE ;
CROM, WR ;
ABROMOWITCH, M ;
DODGE, R ;
LOOK, AT ;
BOWMAN, WP ;
GEORGE, SL ;
PUI, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (08) :471-477
[7]  
HARTMAN N, 1982, CANCER CHEMOTH PHARM, V10, P11
[8]   PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES WITH 4'-EPI-DOXORUBICIN IN NASOPHARYNGEAL CARCINOMA PATIENTS [J].
HU, OYP ;
CHANG, SP ;
JAME, JM ;
CHEN, KY .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 24 (05) :332-337
[9]   LIQUID-CHROMATOGRAPHIC ANALYSIS OF ADRIAMYCIN AND METABOLITES IN BIOLOGICAL-FLUIDS [J].
ISRAEL, M ;
PEGG, WJ ;
WILKINSON, PM ;
GARNICK, MB .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1978, 1 (06) :795-809
[10]  
MILANO G, 1987, CANCER CHEMOTH PHARM, V20, P71